Search 7,500+ licensed pharmacies to find the best value, closest location, and fastest turnaround for
.
Tirzepatide activates both GIP and GLP-1 receptors simultaneously, producing greater insulin secretion, stronger appetite suppression, and more significant weight loss than GLP-1 agonists alone — averaging 20–22% body weight reduction in clinical trials.
Compounded tirzepatide may be prescribed when a commercially available option doesn’t fully meet a patient’s needs. Providers may choose a compounded version for: Customized dosing Flexible titration options Availability during supply issues Cost considerations Individualized treatment plans Compounded medications are prepared by licensed pharmacies pursuant to a valid prescription and are not FDA-approved.
Compare up to 7,500 pharmacies across the USA.
Tirzepatide is a first-in-class dual GIP and GLP-1 receptor agonist. By targeting two incretin hormone pathways simultaneously, it produces superior metabolic effects compared to GLP-1 agonists alone — including the highest weight loss outcomes ever recorded in a pharmaceutical trial, averaging 20–22% body weight reduction.
Like semaglutide, compounded tirzepatide requires a documented medical necessity following removal from the FDA shortage list.
Dual GIP + GLP-1 Agonism
Tirzepatide activates both GIP and GLP-1 receptors simultaneously. GIP enhances insulin secretion and may directly stimulate adipocyte fat breakdown. GLP-1 suppresses appetite and slows gastric emptying. The combination produces additive metabolic benefits exceeding either pathway alone.
Weight Management: Chronic obesity, BMI ≥30 or ≥27 with comorbidity
Type 2 Diabetes: Blood sugar and HbA1c control
Metabolic Syndrome: Insulin resistance, cardiovascular risk reduction
Standard titration: 2.5mg/week × 4 weeks → 5mg → 7.5mg → 10mg → 12.5mg → 15mg maintenance
Each dose step held for minimum 4 weeks.
Common:
Serious (rare):
Submit a quote request to find the lowest price. Quotes delivered to your inbox.
Find Lowest Price.png){kind=spacer}
